(Q50583247)

16 March 2018

title

T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin. (English)

1 reference

16 March 2018

1 reference

D Neau

1

1 reference

16 March 2018

T Galpérine

2

1 reference

16 March 2018

E Legrand

3

1 reference

16 March 2018

V Pitard

4

1 reference

16 March 2018

M Neau-Cransac

5

1 reference

16 March 2018

J F Moreau

6

1 reference

16 March 2018

J M Ragnaud

7

1 reference

16 March 2018

M Dupon

8

1 reference

16 March 2018

H Fleury

9

1 reference

16 March 2018

M E Lafon

10

1 reference

16 March 2018

publication date

1 April 2003

1 reference

16 March 2018

published in

HIV Medicine

1 reference

16 March 2018

volume

4

1 reference

16 March 2018

issue

2

1 reference

16 March 2018

page(s)

120-126

1 reference

16 March 2018

Viruses and interferon: a fight for supremacy

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Impairment of T and B cell development by treatment with a type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

IL-7 is critical for homeostatic proliferation and survival of naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Lifespan of human lymphocyte subsets defined by CD45 isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Dendritic cell susceptibility to hepatitis C virus genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

IFN-alpha suppresses activation of nuclear transcription factors NF-kappa B and activator protein 1 and potentiates TNF-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00140.X

10.1046/J.1468-1293.2003.00140.X

21 January 2018

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018